Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-12-04
2007-12-04
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S367000, C548S161000, C548S335500, C548S338500
Reexamination Certificate
active
11051760
ABSTRACT:
The present invention relates to novel inhibitors of glutaminyl cyclase and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia.
REFERENCES:
patent: 4576957 (1986-03-01), Marsico et al.
patent: 5552426 (1996-09-01), Lunn et al.
patent: 5955548 (1999-09-01), Dorwald et al.
patent: 6448282 (2002-09-01), Phillips et al.
patent: 6979686 (2005-12-01), Naraian et al.
patent: 2005/0026844 (2005-02-01), Hammock et al.
patent: 3210009 (1982-10-01), None
patent: 07068933 (1995-03-01), None
patent: WO 93/01812 (1993-02-01), None
patent: WO 93/20061 (1993-10-01), None
patent: WO 95/22327 (1995-08-01), None
patent: WO 97/43278 (1997-11-01), None
patent: WO 9907672 (1999-02-01), None
patent: WO 99/20599 (1999-04-01), None
patent: WO 9924035 (1999-05-01), None
patent: WO 99/41220 (1999-08-01), None
patent: WO 99/41224 (1999-08-01), None
patent: WO 99/64420 (1999-12-01), None
patent: WO 00/53596 (2000-09-01), None
patent: WO 01/34594 (2001-05-01), None
patent: WO 02/13821 (2002-02-01), None
patent: WO 02/16318 (2002-02-01), None
patent: WO 02016318 (2002-02-01), None
patent: WO 02/066459 (2002-08-01), None
patent: WO 02/092103 (2002-11-01), None
patent: WO 02094813 (2002-11-01), None
patent: WO 03/040174 (2003-05-01), None
patent: WO 03/070732 (2003-08-01), None
patent: WO 03068738 (2003-08-01), None
patent: WO 03095421 (2003-11-01), None
patent: WO 2004026815 (2004-04-01), None
patent: WO 2004/089366 (2004-10-01), None
patent: WO 2004/098591 (2004-11-01), None
patent: WO 2004/098625 (2004-11-01), None
Haley et al. Giorn. Ital. Chemioterap. (1962) 6-9 (No. 3), 213-24. *Abstract from CAS attached.
Hough et al. Pharmacology, Biochemistry and Behavior 1999, 65(1), 61-66. *Abstract from CAS attached.
Morissette et al. Advanced Drug Delivery Reviews 2004, 56, 275-300.
Wright, et al.; “Thromboxane Synthetase Inhibitors and Antihypertensive Agents. 4.N-[(1H-Imidazol-1-yl)alkyl] Derivatives of Quinazoline-2,4(1H,3H)-diones, Quinazolin-4(3H)-ones, and 1,2,3-Benzotriazin-4(3H)-ones”;J. Med. Chem.; 1987, 30, 2277-2283.
Moon, et al.; “Cholinergic Activity of Acetylenic Imidazoles and Related Compounds”;J. Med. Chem.; 1991, 34, 2314-2327.
Venkatachalam, et al.; “Anti-HIV Activity of Aromatic and Heterocyclic Thiazolyl Thiourea Compounds”;Bioorganic&Medicinal Chemistry Letters; (2001) 11, 523-528.
Clader, et al.; “Substituted (1,2-Diarylethyl)amide Acyl-CoA:Cholesterol Acyltransferase Inhibitors: Effect of Polar Groups on in Vitro and in Vivo Activity”;J. Med. Chem.; 1995, 38, 1600-1607.
Wright, et al.; “Thromboxane Synthetase Inhibitors and Antihypertensive Agents. 1. N-[(1H-Imidazol-1-yl)alkyl]aryl Amides and N-[(1H-1,2,4-Triazol-1-yl)alkyl]aryl Amides”;J. Med. Chem.; 1986, 29, 523-530.
Liu, et al.; “Nonpeptide Somatostatin Agonists with sst4Selectivity: Synthesis and Structure-Activity Relationships of Thioureas”;J. Med. Chem.; 1998, 41, 4693-4705.
Ganellin, et al.; “Design of Potent Non-Thiourea H3-Receptor Histamine Antagonists”;J. Med. Chem.; 1995, 38, 3342-3350.
Misquitta, et al.; “Characterization of the Inhibition of Glutaminyl Cyclase by Imidazole Derivatives and Phenanthrolines”Federation of American Societies for Experimental Biology. Annual Meeting; 2002, vol. 16, No. 4, p. A157.
Misquitta, et al.; “Inhibition Studies of Glutaminyl Cyclase”;FASEB Journal; 2001, vol. 15, No. 5, p. A1159.
Schilling, et al.; “Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions”;FEBS Letters; 2004, 563: 191-196.
Muggia, et al.; “Phase I study of amifostine (A) as a cytoprotector of the gencitabine/cisplatin (GP) combination”;European Journal off Cancer, Pergamon Press, Oxford, GB; (2001); 37: S71.
Tsavaris, et al.; “Amifostine, in a Reduced Dose, Protects Against Severe Diarrhea Associated with Weekly Fluorouracil and Folinic Acid Chemotherapy in Advanced Colorectal Cancer: A Pilot Study”;Journal of Pain and Symptom Management; (2003); 26(3): 849-854.
Poplin, et al.; “Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer”;Cancer Chemotherapy and Pharmacology; (1994); 33: 415-419.
Kurbacher and Mallmann; Chemoprotection in Anticancer Therapy: The Emerging Role of Amifostine (WR-2721);Anticancer Research; (1998); 18: 2203-2210.
Schilling, et al.; “Identification of Human Glutaminyl Cyclase as a Metalloenzyme”;The Journal of Biological Chemistry; (2003); 278(50): 49773-49779.
International Search Report for PCT/EP04/011630 dated Apr. 22, 2005.
International Search Report for PCT/EP2004/004778 dated Apr. 13, 2005.
Visser, et al.; “Task-specific ionic liquids for the extraction of metal ions from aqueous solutions”;Chem. Commun.; 2001; 1: 135-136.
Dressman, et al.; “Solid Phase Synthesis of Urea Libraries Using a Diversifiable Thiophenoxy Carbonyl Linker”;Tetrahedron Letters, Elsevier Science Publishers; 1998; 39(22): 3631-3634.
International Search Report for PCT/EP2005/001153 dated Aug. 3, 2005.
Buchholz Mirko
Demuth Hans-Ulrich
Heiser Ulrich
Niestroj André Johannes
Schilling Stephan
Nolan Jason M
Probiodrug (AG)
Saeed Kamal A.
Sonnenschein Nath & Rosenthal LLP
LandOfFree
Inhibitors of glutaminyl cyclase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of glutaminyl cyclase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of glutaminyl cyclase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3897152